* SAGE THERAPEUTICS REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 2 PLACEBO-CONTROLLED TRIAL OF SAGE-217 IN MAJOR DEPRESSIVE DISORDER


20


Reuters